Skip to content
MarketScale
‹ Back to IndustriesSciences

Fifty Years Later, The Space Race is Back On

In the time since Neil Armstrong and Buzz Aldrin first landed on the moon on July 20, 1969, only 10 other men have walked on the lunar surface. Fifty years after this marvel of human achievement, there is a new desire to go back, not simply for exploration’s sake, but for commercial reasons. Never before…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Geoff Short · Apollo 11Blue OriginBuzz AldrinElon Musk
Share
Fifty Years Later, The Space Race is Back On

Key takeaways

01

In the time since Neil Armstrong and Buzz Aldrin first landed on the moon on July 20, 1969, only 10 other men have walked on the lunar surface.

02

Fifty years after this marvel of human achievement, there is a new desire to go back, not simply for exploration’s sake, but for commercial reasons.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

In the time since Neil Armstrong and Buzz Aldrin first landed on the moon on July 20, 1969, only 10 other men have walked on the lunar surface. Fifty years after this marvel of human achievement, there is a new desire to go back, not simply for exploration’s sake, but for commercial reasons.

Never before have there been as many space-oriented startups as there are today, and public-private relationships are developing quickly across the United States.

The Public-Private Push

The Trump administration has laid out a plan to return to the moon by 2024 with the goal to have a sustained presence by 2028, and entrepreneurs are racing climb aboard. Whether this is a realistic goal remains to be seen.

Billionaires Elon Musk and Jeff Bezos have publicly led the movement with their companies SpaceX and Blue Origin, respectively. Entrepreneurs from across the globe, and the venture capitalists backing them see an opportunity for tourism among the stars, resource mining, and a potential launching pad to planets including Mars.

For the first time since the 1960s, a genuine space race is officially heating up.

According to the Wall Street Journal, 90 percent of the $8.4 billion that has been spent by venture capitalists on space startups has been done in the past five years alone.

The Uncertain Horizon

Still, questions remain about the return on investment of the moon. With uncertainty about the timeline and ultimate plans, some investors remain leery.

The U.S. government however, seeing China and Russia gear up for trips to the moon, has little choice but to hand out contracts to private companies intent on getting there quickly.

Startups with application in everything from defense to hospitality are vying for access to the moon and Mars, and competition is accelerating the process of a return to the lunar surface.

For more on the space race head to our science page!

Make sure to follow us on Twitter at @ScienceMKSL.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

GS
Geoff Short

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

GS
Geoff Short

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512